An underestimated combination of opposites resulting in enhanced thrombotic tendency

被引:45
作者
Simioni, P
Castoldi, E
Lunghi, B
Tormene, D
Rosing, J
Bernardi, F
机构
[1] Univ Padua, Sch Med, Dept Med & Surg Sci, Chair Internal Med 2, I-35100 Padua, Italy
[2] Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Biochem, Maastricht, Netherlands
[3] Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy
关键词
D O I
10.1182/blood-2005-04-1461
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heterozygous carriers of factor V (FV) Leiden who also carry FV deficiency often develop venous thromboembolism, but the thrombosis risk associated with this rare condition (pseudohomozygous activated protein C resistance) is still unclear. The thrombosis risk of genetically characterized pseudohomozygotes (n = 6) was compared with that of FV Leiden heterozygotes (n = 683) and homozygotes (n = 50) recruited within a large cohort study on familial thrombophilia. Both thrombin generation and Kaplan-Meier thrombosis-free survival analyses were performed in different FV genotype groups. FV Leiden pseudohomozygotes showed significantly higher thrombosis risk than heterozygotes. The thrombin generation test in pseudohomozygotes showed a pattern similar to homozygotes. Accordingly, early thrombotic manifestations occurred in pseudohomozygotes at a similar rate as in homozygotes. Thus, failure to recognize FV deficiency in FV Leiden heterozygotes may result in an underestimate of the thrombosis risk and inadequate management of affected patients.
引用
收藏
页码:2363 / 2365
页数:3
相关论文
共 16 条
[1]   Rare bleeding disorder registry: Deficiencies of factors II, V, VII, X, XIII fibrinogen and dysfibrinogenemias [J].
Acharya, SS ;
Coughlin, A ;
DiMichele, DM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (02) :248-256
[2]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[3]   Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis [J].
Castaman, G ;
Tosetto, A ;
Ruggeri, M ;
Rodeghiero, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (01) :232-236
[4]   Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma [J].
Castoldi, E ;
Kalafatis, M ;
Lunghi, B ;
Simioni, P ;
Ioannou, PA ;
Petio, M ;
Girolami, A ;
Mann, KG ;
Bernardi, F .
THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) :403-406
[5]   Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations [J].
Castoldi, E ;
Brugge, JM ;
Nicolaes, GAF ;
Girelli, D ;
Tans, G ;
Rosing, J .
BLOOD, 2004, 103 (11) :4173-4179
[6]  
Castoldi E, 2001, HAEMATOLOGICA, V86, P629
[7]  
Curvers J, 2002, THROMB HAEMOSTASIS, V88, P5
[8]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[9]  
GREENGARD JS, 1995, THROMB HAEMOSTASIS, V73, P1361
[10]  
OLDS R, 2003, J THROMB HAEMOST, V1, pP1206